Trovagene Inc., a San Diego molecular diagnostics company, said it secured an unrestricted debt facility of $15 million from Silicon Valley bank and Oxford Finance LLC.

The company said the additional capital will be used to support ongoing activities for its precision cancer monitoring platform. Trovagene said it expects to report about $35 million in cash and cash equivalents for the quarter ended June 30.